Advertisement

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, Nelly Robillard, Cyrille Hulin, Marie-Lorraine Chretien, Thomas Dejoie, Sabrina Maheo, Anne-Marie Stoppa, Brigitte Pegourie, Lionel Karlin, Laurent Garderet, Bertrand Arnulf, Chantal Doyen, Nathalie Meuleman, Bruno Royer, Jean-Richard Eveillard, Lotfi Benboubker, Mamoun Dib, Olivier Decaux, Arnaud Jaccard, Karim Belhadj, Sabine Brechignac, Brigitte Kolb, Cecile Fohrer, Mohamad Mohty, Margaret Macro, Paul G. Richardson, Victoria Carlton, Martin Moorhead, Tom Willis, Malek Faham, Kenneth C. Anderson, Jean-Luc Harousseau, Xavier Leleu, Thierry Facon, Philippe Moreau, Michel Attal, Hervé Avet-Loiseau and Nikhil Munshi

Article Information

Citation 
vol. 132 no. 23 2456-2464
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted June 20, 2018
  • Accepted August 28, 2018
  • Published online December 6, 2018.

Article Versions


Contributors 
  • Aurore Perrot, 1Hematology Department, University Hospital, Nancy, France;
  • Valerie Lauwers-Cances, 2Epidemiology and Statistics Department, University Hospital, Toulouse, France;
  • Jill Corre, 3Myeloma Genomics Lab University Cancer Institute Toulouse (IUCT)-Oncopole, Cancer Research Center of Toulouse (CRCT), INSERM 1037, Toulouse, France; 4Université Paul Sabatier, Toulouse, France;
  • Nelly Robillard, 5Hematology Laboratory, University Hospital, Nantes, France;
  • Cyrille Hulin, 6Hematology Department, University Hospital, Bordeaux, France;
  • Marie-Lorraine Chretien, 7Hematology Department, University Hospital, Dijon, France;
  • Thomas Dejoie, 8Biochemistry Laboratory, University Hospital, Nantes, France;
  • Sabrina Maheo, 3Myeloma Genomics Lab University Cancer Institute Toulouse (IUCT)-Oncopole, Cancer Research Center of Toulouse (CRCT), INSERM 1037, Toulouse, France; 4Université Paul Sabatier, Toulouse, France;
  • Anne-Marie Stoppa, 9Hematology Department, Institut Paoli Calmettes, Marseille, France;
  • Brigitte Pegourie, 10Hematology Department, University Hospital, Grenoble, France;
  • Lionel Karlin, 11Hematology Department, University Hospital, Lyon, France;
  • Laurent Garderet, 12Hematology Department, Saint-Antoine University Hospital, Paris, France;
  • Bertrand Arnulf, 13Hematology Department, Saint-Louis University Hospital, Paris, France;
  • Chantal Doyen, 14Hematology Department, Centre Hospitalier Universitaire (CHU) Université Catholique de Louvain (UCL) Namur, Yvoir, Belgium;
  • Nathalie Meuleman, 15Hematology Department, Institut Jules Bordet (ULB), Brussels, Belgium;
  • Bruno Royer, 16Hematology Department, University Hospital, Amiens, France;
  • Jean-Richard Eveillard, 17Hematology Department, University Hospital, Brest, France;
  • Lotfi Benboubker, 18Hematology Department, University Hospital, Tours, France;
  • Mamoun Dib, 19Hematology Department, University Hospital, Angers, France;
  • Olivier Decaux, 20Hematology Department, University Hospital, Rennes, France;
  • Arnaud Jaccard, 21Hematology Department, University Hospital, Limoges, France;
  • Karim Belhadj, 22Hematology Department, University Hospital, Creteil, France;
  • Sabine Brechignac, 23Hematology Department, University Hospital, Bobigny, France;
  • Brigitte Kolb, 24Hematology Department, University Hospital, Reims, France;
  • Cecile Fohrer, 25Hematology Department, University Hospital, Strasbourg, France;
  • Mohamad Mohty, 12Hematology Department, Saint-Antoine University Hospital, Paris, France;
  • Margaret Macro, 26Hematology Department, University Hospital, Caen, France;
  • Paul G. Richardson, 27Hematology Department, Dana-Farber Cancer Institute, Boston, MA;
  • Victoria Carlton, 28Adaptive Biotechnologies, Seattle, WA;
  • Martin Moorhead, 28Adaptive Biotechnologies, Seattle, WA;
  • Tom Willis, 28Adaptive Biotechnologies, Seattle, WA;
  • Malek Faham, 28Adaptive Biotechnologies, Seattle, WA;
  • Kenneth C. Anderson, 27Hematology Department, Dana-Farber Cancer Institute, Boston, MA;
  • Jean-Luc Harousseau, 29Hematology Department, Clinique du Confluent, Nantes, France;
  • Xavier Leleu, 30Hematology Department, University Hospital, Poitiers, France;
  • Thierry Facon, 31Hematology Department, University Hospital, Lille, France;
  • Philippe Moreau, 32Hematology Department, University Hospital, Nantes, France; and
  • Michel Attal, 33Hematology Department, University Hospital, Toulouse, France
  • Hervé Avet-Loiseau, 3Myeloma Genomics Lab University Cancer Institute Toulouse (IUCT)-Oncopole, Cancer Research Center of Toulouse (CRCT), INSERM 1037, Toulouse, France; 4Université Paul Sabatier, Toulouse, France;
  • Nikhil Munshi, 27Hematology Department, Dana-Farber Cancer Institute, Boston, MA;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output